Filing Flows › Biofrontera (BFRI) › Q2 2026 › vs Q1 2026
Biofrontera (BFRI) Q2 2026 vs Q1 2026 (quarter over quarter)
Biofrontera's revenue rose $1.9M (+19%) from $10.1M in Q1 2026 to $12.0M in Q2 2026.
Biofrontera, Q2 2026: revenue $12.0M (+33% year over year), operating margin -4.4%, net loss $604K, operating cash flow −$1.7M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $12.0M | $10.1M | $1.9M | +19% |
| Net loss | $604K | $4.8M | −$4.1M | -87% |
| Costs & expenses | $12.6M | $14.8M | −$2.2M | -15% |
| Operating costs | $12.5M | $14.4M | −$1.9M | -13% |
| Interest & other, net | $57K | $432K | −$375K | -87% |
| Income tax | $23K | $0 | $23K | — |
| Research & development | $448K | $900K | −$452K | -50% |
| SG&A | $9.6M | $11.0M | −$1.4M | -12% |
| Other operating costs | $2.5M | $2.5M | −$59K | -2% |
| Operating cash sources | $2.0M | $467K | $1.5M | +325% |
| Depreciation & amortization | $65K | $55K | $10K | +18% |
| Share-based compensation | $263K | $342K | −$79K | -23% |
| Cash used in operations | $1.7M | $70K | $1.6M | 24× |
| Net loss absorbed | $604K | $4.8M | −$4.1M | -87% |
| Working capital & other | $1.4M | −$4.3M | $5.7M | — |
Questions
How much did Biofrontera's revenue grow quarter over quarter in Q2 2026?
Biofrontera's revenue rose $1.9M (+19%) from $10.1M in Q1 2026 to $12.0M in Q2 2026.